Davy Research

Amryt Pharma

Distribution agreement signed for Lojuxta covering Central and Eastern Europe
Pharma and healthcare
Amryt Pharma

DAVY VIEW

Amryt continues to build out its presence in its licensed territories for Lojuxta, having signed an exclusive distribution agreement with GryNumber Health that covers Central and Eastern Europe. It is Amryt’s third distribution agreement signed in the last three months. This follows the agreement signed in Switzerland on January 8th with RCC Pharma and the agreement signed with El Seif in the key commercial territory of Saudi Arabia in November 2017.

Download full report with analyst certification and important disclosures
Download
Download full report with analyst certification and important disclosures
Download
  • RATINGS AND PRICE CORRECT AT TIME OF ISSUE


  • Amryt Pharma

    Closing Price: 2000p

  • RATING 14/09/17

  • PREVIOUS RATING N/A

Analyst(S)

COMPANY DATA

JUMP TO